Eminent Member of the Austrian Academy of Sciences, Professor Uwe B. Sleytr, Joins Avalon GloboCare's Scientific and Clinical...
June 16 2020 - 9:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global
developer of cell-based technologies and therapeutics, announced
today that the Company has appointed Professor Uwe B. Sleytr to its
Scientific and Clinical Advisory Board.
Professor Uwe B. Sleytr is a world-renowned
scientist and pioneer in nanobiotechnology. He is Professor
Emeritus in the Department of Nanobiotechnology at the University
of Natural Resources and Life Sciences (UNRLS) in Vienna, Austria.
He held a long tenure as the Head of the Center for Ultrastructure
Research at the UNRLS Vienna from 1980 to 2010 and also served as
Director of the Vienna-based Ludwig Boltzmann Institute for
Molecular Nanotechnology. Professor Sleytr is among the foremost
experts on basic and applied surface layer (“S-layer”) technology
and is credited with coining the term ‘S-layer.’ He is a prolific
researcher having co-authored more than 420 peer-reviewed
scientific articles and has penned five books on S-layers and other
research topics. Over the course of his career, Professor Sleytr
has accomplished seminal achievements in S-layer research. He
identified the way S-layer proteins rearrange and self-assemble on
the surface of certain bacterial species, a breakthrough finding
that was published in the top-ranked scientific journal Nature.
Professor Sleytr also pioneered the first nanobiotechnological
application of S-layer proteins, for the production of
ultrafiltration membranes, and demonstrated that S-layer technology
could be used as a combined carrier and adjuvant for certain types
of vaccines.
Professor Sleytr is a full member of the Austrian
Academy of Sciences since 1994 and has been an active member of the
European Academy of Sciences and Arts since 2008. He has received
numerous international honors and awards throughout his career,
including the prestigious EUREKA Award for Inventors, the Wilhem
Exner Medal, the Innitzer Award for Natural Sciences, and the
Schwackhöfer Award of the Austrian Society for Food and
Biotechnology.
Avalon plans to engage in co-development projects
with Professor Sleytr on novel applications of S-layer technology,
integrating biomedical science and engineering. Based on its unique
structural features, S-layers have potential in innovative vaccine
and nanoparticle development, targeted drug delivery, and other
diagnostic and therapeutic applications.
“We are pleased and honored to welcome Professor
Sleytr to our Scientific and Clinical Advisory Board,” stated David
Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon
GloboCare. “Professor Sleytr brings a wealth of expertise on
translational research and an impressive depth of knowledge on the
applications of S-layer research that are highly relevant to
Avalon’s scientific and clinical programs.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a
clinical-stage, vertically-integrated, leading CellTech
bio-developer dedicated to advancing and empowering innovative,
transformative immune effector cell therapy, exosome technology, as
well as COVID-19 related diagnostics and therapeutics. Avalon also
provides strategic advisory and outsourcing services to facilitate
and enhance its clients' growth and development, as well as
competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of
verticals from innovative R&D to automated bioproduction and
accelerated clinical development, Avalon is establishing a leading
role in the fields of cellular immunotherapy (including CAR-T/NK),
exosome technology (ACTEX™), and regenerative therapeutics. For
more information about Avalon GloboCare, please visit
www.avalon-globocare.com.
Forward-Looking Statements
Certain statements contained in this press release
may constitute "forward-looking statements." Forward-looking
statements provide current expectations of future events based on
certain assumptions and include any statement that does not
directly relate to any historical or current fact. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors as disclosed in
our filings with the Securities and Exchange Commission located at
their website (http://www.sec.gov). In addition to these factors,
actual future performance, outcomes, and results may differ
materially because of more general factors including (without
limitation) general industry and market conditions and growth
rates, economic conditions, and governmental and public policy
changes. The forward-looking statements included in this press
release represent the Company's views as of the date of this press
release and these views could change. However, while the Company
may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to
do so. These forward-looking statements should not be relied upon
as representing the Company's views as of any date subsequent to
the date of the press release.
Contact Information:Avalon GloboCare Corp.4400 Route 9, Suite
3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Sep 2023 to Sep 2024